BRAF V600E‐specific immunohistochemistry for the exclusion of Lynch syndrome in MSI‐H colorectal cancer
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The differentiation between hereditary and sporadic microsatellite‐unstable (MSI‐H) colorectal cancer is a crucial step in Lynch syndrome diagnostics. Within MSI‐H colorectal cancers, the BRAF V600E mutation is strongly associated with sporadic origin. Here, we asked whether BRAF V600E‐specific immunohistochemistry (clone VE1) is helpful in separating sporadic from Lynch syndrome‐associated MSI‐H colorectal cancers. To that end, we performed VE1 immunohistochemistry and BRAF sequencing in a series of 91 MSI‐H colorectal cancer specimens from patients tested for Lynch syndrome. Concordance of VE1 immunohistochemistry and molecular BRAF mutation status was observed in 90 of 91 (98.9%) MSI‐H samples. All 11 tumors classified as BRAF V600E mutation‐positive by Sanger sequencing were immunopositive, and 79 (98.8%) of 80 tumors classified as BRAF wild type showed negative staining. All VE1‐positive tumors were MLH1‐ and PMS2‐negative by immunohistochemistry. None of the tumors from mismatch repair (MMR) gene germline mutation carriers (n = 28) displayed positive VE1 staining, indicating that BRAF V600E mutation‐specific immunostaining has a low risk of excluding Lynch syndrome patients from germline mutation analysis. In conclusion, implementation of VE1 immunohistochemistry was able to detect BRAF‐mutated MSI‐H colorectal cancers with a sensitivity of 100% and a specificity of 98.8%. Among MLH1‐negative colorectal cancers, the rate of VE1‐positive lesions was 21%, offering the exclusion of these patients from MMR germline testing. Therefore, we suggest the integration of VE1 immunohistochemistry into the diagnostic panel of Lynch syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
Richman, S. D., Seymour, M. T., Chambers, P., Elliott, F., Daly, C. L., Meade, A. M., Taylor, G., Barrett, J. H., & Quirke, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4295 · Cited by 560 · cited 2×
“BRAF mutations found in colorectal cancer almost invariably result in substitution of valine to glutamate at residue 600 (BRAF V600E) and occur at a frequency of 8–10%.(15,16) Although BRAF mutations are virtually absent in hereditary colorectal”
BackgroundResult
Cited by
Mucinous colorectal adenocarcinoma: clinical pathology and treatment options
Luo, C., Cen, S., Ding, G., & Wu, W. (2019) · Cancer Communications · doi:10.1186/s40880-019-0361-0 · Cited by 313
Microsatellite instability: an update
Yamamoto, H., & Imai, K. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1474-0 · Cited by 247
The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
Mauri, G., Bonazzina, E., Amatu, A., Tosi, F., Bencardino, K., Gori, V., Massihnia, D., Cipani, T., Spina, F., Ghezzi, S., et al. (2021) · Cancers · doi:10.3390/cancers13010137 · Cited by 73
Toon, C. W., Chou, A., DeSilva, K., Chan, J., Patterson, J., Clarkson, A., Sioson, L., Jankova, L., & Gill, A. J. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.200 · Cited by 59
Metadata
- Authors
- Capper, D., Voigt, A., Bozukova, G., Ahadova, A., Kickingereder, P., von Deimling, A., von Knebel Doeberitz, M., & Kloor, M.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2013-04-25
- Volume
- 133
- Issue
- 7
- Pages
- 1624-1630
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1495328874
- Cited by
- 109
- References
- 2
- FWCI
- 12.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BRAF V600E‐specific immunohistochemistry for the exclusion of Lynch syndrome in MSI‐H colorectal cancer. https://app.cochat.ai/papers/10.1002/ijc.28183
- The paper
- Capper, D., Voigt, A., Bozukova, G., Ahadova, A., Kickingereder, P., von Deimling, A., von Knebel Doeberitz, M., & Kloor, M. (2013). BRAF V600E‐specific immunohistochemistry for the exclusion of Lynch syndrome in MSI‐H colorectal cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.28183
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.